Using the national cancer institute anticancer drug screen to assess the effect of MRP expression on drug sensitivity profiles

Molecular Pharmacology

Volumn 54, Issue 5, 1998, Pages 802-814

  Alvarez, M ^a   Robey, R ^b   Sandor, V ^b   Nishiyama, K ^b   Matsumoto, Y ^b   Paull, K ^b   Bates, S ^b   Fojo, T ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CALCEIN; DOXORUBICIN; ETOPOSIDE; GLUTATHIONE; LEUKOTRIENE C4; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; VINCRISTINE;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CORRELATION FUNCTION; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTER; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MEMBRANE VESICLE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0031724520     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.54.5.802     Document Type: Article

References (37)

1. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, Grever MR, Bates SE, and Fojo AT (1995) Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the NCI Anticancer Drug Screen. J Clin Invest 95:2205-2214.
2. Baldini N, Scotlandi K, Barbanti-Brodano G, Manara MC, Maurici D, Bacci G, Bertoni F, Picci P, Sottili S, Campanacci M, and Serra M (1995) Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med 333:1380-1385.
3. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, and Gekeler V (1995) Expression of mdr1, mrp, topoisomerase IIα/B, and cyclin A in primary or relapsed states of acute lymphoblastic leukaemias. Br J Haematol 89:356-363.
4. Bhalla K, Hindenburg A, Taub RN, and Grant S (1985) Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res 45:3657-3662.
5. Bordow SB, Haber M, Madafiglio J, Cheung B, Marshall GM, and Norris MD (1994) Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma. Cancer Res 54:5036-5040.
6. Boyd MR, Paull KD, and Rubinstein LR (1992) Data display and analysis strategies for the NCI Disease Oriented In-Vitro Antitumor Drug Screen, in Cytotoxic Anticancer Drugs: Models and Concept for Drug Discovery and Development (Valeriote FA, Corbett TH, and Baker LH, eds.) pp 11-34, Boston, Kluwer Academic Publishers.
7. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-256.
8. Brock I, Hipfner DR, Nielsen BS, Jensen PB, Deeley RG, Cole SP, and Sehested M (1995) Sequential coexpression of the multidrug resistance genes MRP and mdr1 and their products in VP-16 (etoposide)-selected H69 small cell lung cancer cells. Cancer Res 55:459-462.
9. Cornwell MM, Gottesman MM, and Pastan IH (1986) Increased vinblastine binding to membrane vesicles from multidrug-resistant KB cells. J Biol Chem 261:7921-7928.
10. Doyle LA, Ross DD, Ordonez JV, Yang W, Gao Y, Tong Y, Belani CP, and Gutheil JC (1995) An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br J Cancer 72:535-542.
11. Feller N, Broxterman HJ, Wahrer DCR, and Pinedo HM (1995) ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): no inhibition by intracellular glutathione depletion. FBBS Lett 368:385-388.
12. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, and Lewis AD (1996) Reductase enzyme expression across the National Cancer Institute tumor cell line panel: correlation with sensitivity to mitomycin C and E09. J Natl Cancer Inst 88:259-269.
13. Freije JM, Lawrence JA, Hollingshead MG, De la Rosa A, Narayanan V, Grever M, Sausville EA, Paull K, and Steeg PS (1997) Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. Nat Med 3:395-401.
14. Hasegawa S, Abe T, Naito S, Kotoh S, Kumazawa J, Hipfner DR, Deeley RG, Cole SPC, and Kuwano M (1996) Expression of multidrug resistance-associated protein (MRP), MDR1 and DNA topoisomerase II in human multidrug-resistant bladder cancer cell lines. Br J Cancer 71:907-913.
15. 2+ dependent cardiac transport system for glutathione S-conjugates: a study using rat heart sarcolemma vesicles. J Biol Chem 264: 17343-17348.
16. Ishikawa T and Ali-Osman F (1993) Glutathione-associated cis-diamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J Biol Chem 268:20116-20125.
17. Jedlitschky G, Leier I, Buchholz U, Barnouin K, Kurz G, and Keppler D (1996) Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56:988-994.
18. Jedlitschky G, Leier I, Buchholz U, Center M, and Keppler D (1994) ATP-dependent transport of glutathion S-conjugates by multidrug resistance-associated protein. Cancer Res 54:4833-4836.
19. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, and Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute Drug Screen. Mol Pharmacol 46:627-638.
20. Leier I, Jedlitschky G, Buchholz U, and Keppler D (1994) Characterization of the ATP-dependent leukotrien C4 export carrier in mastocytoma cells. Ear J Biochem 220:599-606.
21. - cases. Blood 86:2329-2342.
22. Loe DW, Almquist KC, Cole SPC, and Deeley RG (1996a) ATP-dependent 17 β-estradiol 17-(β-D-glucuronide) transport by multidrug resistance protein (MRP). J Biol Chem 271:9683-9689.
23. Loe DW, Almquist KC, Deeley RG, and Cole SPC (1996b) Multidrug resistance protein (MRP)-mediated transport of leukotriene C4 and chemotherapeutic agents in membrane vesicles: demonstration of glutathione-dependent vincristine transport. J Biol Chem 271:9675-9682.
24. Matsumoto Y, Takano H, and Fojo T (1997) Cellular adaptation to drug exposure: evolution of the drug-resistant phenotype. Cancer Res 57:5086-5092.
25. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J, and Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766.
26. Muller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, deVries EGE, and Jansen PLM (1994) Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91:13033-13037.
27. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S Jr, Fornace AJ, and Kohn KW (1997) Characterization of the p52 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer drugs. Cancer Res 57:4285-4300.
28. Paull KD, Hamel E, and Malspeis L (1995) Prediction of biochemical mechanisms of action from the in vitro antitumor screen of the National Cancer Institute, in Cancer Chemotherapeutic Agents (Foye WE, ed.) pp 9-45, Washington, DC, American Chemical Society.
29. Paull KD, Lin CM, Malspeis L, and Hamel E (1992) Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 52:3892-3900.
30. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J, and Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and Compare algorithm. J Natl Cancer Inst 81:1088-1092.
31. Schneider E, Horton JK, Yang C, Nakagawa M, and Cowan KC (1994) Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etopside resistance. Cancer Res 54:152-158.
32. Shen H, Paul S, Breuninger LM, Ciaccio PJ, Laing NM, Helt J, Tew KD, and Kruh GD (1996) Cellular and in vitro transport of glutathione conjugates by MRP. Biochem 35:5719-5723.
33. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicty assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112,
34. Versantvoort CHM, Bagrij T, Wright KA, and Twentyman PR (1995) On the relationship between the probenecid-sensitive transport of daunorubicin or calcein and the glutathione status of cells overexpressing the multidrug resistance-associated protein (MRP). Int J Cancer 63:855-862.
35. Wosikowski K, Schuurhuis D, Johnson K, Paull KD, Myers TG, Weinstein JN, and Bates SE (1997) Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. Cancer Res 57:4285-4300.
36. Zaman GJR, Lankelma J, van Tellingen O, Beijen J, Dekker H, Paulusma C, Oude Elferink RPJ, Baas F, and Borst P (1995) Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein. Proc Natl Acad Sci USA 92:7690-7694.
37. Zhan Z, Sandor VA, Gamelin E, Regis J, Dickstein B, Wilson W, Fojo AT, and Bates SE (1997) Expression of the multidrug resistance-associated protein gene in refractory lymphoma: quantitation by a validated polymerase chain reaction assay. Blood 89:3795-3800.